Licensed providers. In-home visits in Las Vegas, North Las Vegas and Brooklyn, NY.
(718) 218-4791info@briyahealth.comA plain-language look at the GLP-1 medication behind Ozempic, Wegovy and Rybelsus — how it acts on appetite and blood sugar, what the major clinical trials measured, how dosing is stepped up, and what the FDA label says about risks.
Medically reviewed by Jonathan Paul Navar, MD, and David Kotlarsky, PA-C, with the Briya Health medical team.
Semaglutide is the active ingredient; Ozempic, Rybelsus and Wegovy are brand names for it, all made by Novo Nordisk. Ozempic and Rybelsus are labeled for type 2 diabetes. Wegovy is labeled for chronic weight management, for reducing cardiovascular risk in certain adults, and for a form of fatty liver disease. Same molecule, different doses and different approved uses.
Both are weekly semaglutide injections, but they are approved for different things and reach different doses. Ozempic is approved for type 2 diabetes and tops out at 2 mg weekly. Wegovy is approved for weight management, with a 2.4 mg weekly maintenance dose and a higher 7.2 mg option. Because the approved use differs, so does the prescribing rationale and, often, insurance coverage.
Rybelsus is semaglutide in tablet form, taken once daily, and it was the first oral GLP-1 approved in the United States, in 2019, for type 2 diabetes. Its label was later expanded to cover reducing the risk of major cardiovascular events in adults with type 2 diabetes at elevated risk. It is a diabetes medication, not a weight-management one.
Yes. In December 2025 the FDA approved Wegovy tablets, a once-daily 25 mg oral semaglutide, making it the first oral GLP-1 approved for weight management. It is also approved to reduce the risk of major cardiovascular events. Novo Nordisk launched it in the United States in early January 2026. Tablets are supplied in 1.5, 4, 9 and 25 mg strengths and are taken on an empty stomach.
Semaglutide is a GLP-1 analogue that shares about 94% of its sequence with the natural human hormone GLP-1, and it binds to and activates the same receptor. Doing so prompts insulin release when blood sugar is high, reduces glucagon, slows how fast the stomach empties, and acts on receptors in brain regions involved in appetite regulation. The net effect is less hunger, earlier fullness, and steadier blood sugar.
In the STEP 1 trial, adults without diabetes taking 2.4 mg weekly lost an average of 14.9% of body weight at 68 weeks, compared with 2.4% on placebo. About 86% lost at least 5% of their weight and roughly half lost 15% or more. The oral 25 mg version produced 13.6% average loss at 64 weeks in the OASIS 4 trial, or 16.6% among participants who took it as directed. Individual results vary widely around those averages.
Appetite changes are often noticeable within the first few weeks, but the standard titration means the full 2.4 mg dose is not reached until around week 16. Weight change accumulates over many months rather than arriving quickly. In the SELECT trial, weight loss continued for roughly 65 weeks before leveling off, and was then sustained for up to four years of treatment.
For Wegovy injection, treatment starts at 0.25 mg once weekly and steps up roughly every four weeks through 0.5 mg, 1 mg and 1.7 mg before reaching the 2.4 mg maintenance dose at about week 16. The early doses are not intended to treat anything on their own; they exist to let the body adjust and to blunt nausea. Providers may hold a step longer if side effects are difficult.
Wegovy HD is a higher-dose weekly injection, 7.2 mg, intended as a step up for people whose response to 2.4 mg is inadequate. In the STEP UP trial it produced 18.7% average weight loss at 72 weeks versus 3.9% on placebo, and about 31% of participants lost a quarter or more of their body weight. The trade-off is tolerability: gastrointestinal side effects were more frequent, and dysesthesia, an altered skin sensation, was reported far more often at 7.2 mg than at 2.4 mg.
The injection goes under the skin of the abdomen, thigh or upper arm, once a week, on the same day each week. It can be taken at any time of day, with or without food, and the injection site should be rotated. The weekly day can be changed if needed as long as the last two doses were at least 48 hours apart.
The labeled guidance is that if the next scheduled dose is more than two days away, take the missed dose as soon as possible; if it is less than two days away, skip it and resume the normal schedule. If more than two consecutive weekly doses are missed, the dose may need to be re-titrated rather than resumed at full strength, so contact your provider rather than guessing.
Gastrointestinal effects dominate: nausea, vomiting, diarrhea, constipation and abdominal pain. In the oral semaglutide trial, gastrointestinal events affected 74% of participants versus 42% on placebo, and were mostly mild or moderate. They cluster around the start of treatment and around each dose increase, then generally settle.
For most people it eases within a few weeks at a given dose, then may flare briefly after each step up. The practical measures that tend to help are eating smaller meals more often, avoiding greasy, fried or heavily spiced food, drinking fluids steadily, and stopping before feeling completely full. If nausea is severe or persistent, a provider may hold the dose at its current step rather than advancing.
The label lists two absolute contraindications: a personal or family history of medullary thyroid carcinoma, and multiple endocrine neoplasia syndrome type 2. It is also contraindicated in anyone with a known serious hypersensitivity to semaglutide. Beyond those, a history of pancreatitis, gallbladder disease, diabetic retinopathy, severe gastrointestinal disease or pregnancy all warrant a careful conversation before starting.
In rodents, semaglutide caused thyroid C-cell tumors at doses comparable to human exposures. Whether this translates to humans is unknown, because rodent and human thyroid C-cells differ in ways that may make the finding species-specific. The FDA still requires the warning, the contraindications above, and counseling on symptoms worth reporting: a lump in the neck, hoarseness, trouble swallowing, or persistent shortness of breath.
Acute pancreatitis is listed in the prescribing information as a rare but serious adverse event, and the label directs that the drug be stopped if it is suspected. In randomized trials in people with obesity, pancreatitis events were infrequent and occurred at rates comparable to placebo. The symptom that matters is severe, persistent abdominal pain, sometimes radiating to the back, which warrants prompt medical attention.
A possible association with non-arteritic anterior ischemic optic neuropathy, a rare condition causing sudden vision loss in one eye, emerged from a 2024 Harvard study and subsequent database analyses. The European Medicines Agency reviewed the evidence and concluded it is a very rare side effect, recommending it be added to European labels. United States labels did not carry that warning as of this writing. Separately, worsening of existing diabetic retinopathy has been observed with rapid improvements in blood sugar. Any sudden vision change should be reported immediately.
Weight lost through any substantial calorie deficit includes some lean mass, and that is true here as well. This is why adequate protein intake and regular resistance training are consistently emphasized during treatment. The relevant measure is body composition over time rather than the number on the scale alone.
Gallbladder disease, including gallstones, appears in the warnings section of the label. Rapid or substantial weight loss is itself a known risk factor for gallstones, so the effect is difficult to separate from the weight loss the medication produces. Symptoms worth reporting include upper right abdominal pain, fever, yellowing of the skin or eyes, and clay-colored stools.
Typically yes, at least in part. In the STEP 1 extension, participants who had lost 17.3% of their body weight regained about 11.6 percentage points of it during the year after stopping, ending roughly 5.6% below where they started. Improvements in blood pressure, cholesterol and blood sugar also drifted back toward baseline. This is the main reason obesity medicine treats these medications as long-term therapy rather than a short course.
The most clinically important interaction is with insulin and insulin secretagogues such as sulfonylureas, where doses often need to be reduced to avoid low blood sugar. Because semaglutide slows gastric emptying, the label advises monitoring the effect of oral medications taken alongside it, though clinical pharmacology studies with the 1 mg weekly injection found it did not meaningfully change absorption of oral drugs. With the tablet form, levothyroxine exposure increased by about a third, so thyroid levels warrant monitoring.
This is a point where semaglutide and tirzepatide differ. Clinical pharmacology studies of injectable semaglutide found it did not affect the absorption of orally administered medications, and its label carries no special contraceptive instruction. Tirzepatide does carry one, advising a switch to a non-oral method or an added barrier method around starting and each dose increase. If you are weighing the two medications and rely on oral contraception, it is worth raising directly with your provider.
There is no absolute prohibition, but alcohol independently irritates the stomach and pancreas, which can compound the nausea and reflux the medication already tends to cause. It can also contribute to low blood sugar in anyone also taking insulin or a sulfonylurea. Many people find their tolerance for alcohol changes noticeably during treatment. This is worth raising with a provider rather than assuming either way.
It is not recommended in pregnancy. Animal studies showed potential harm to a developing fetus, and weight loss itself is not advised during pregnancy. Because the drug clears slowly, the label advises stopping at least two months before a planned pregnancy. Anyone who becomes pregnant while taking it should contact their provider promptly.
In the SELECT trial, which enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced major adverse cardiovascular events by 20% compared with placebo. That finding led to the cardiovascular indication now on the Wegovy label. A prespecified analysis also found lower rates of a composite kidney outcome.
Yes, in a specific form. In August 2025 the FDA granted accelerated approval for noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced fibrosis. In part one of the ESSENCE trial, about 63% of people on semaglutide achieved resolution of steatohepatitis without worsening fibrosis, versus 34% on placebo, and 37% showed fibrosis improvement versus 22%. It is not approved for MASH with cirrhosis, and confirmatory results are expected in 2029.
The Wegovy injection label was expanded in 2022 to include adolescents aged 12 and older with obesity. In the STEP TEENS trial, average BMI fell 16.1% over 68 weeks versus a slight increase on placebo. The oral tablets have not been established as safe or effective under 18.
Yes, and that is precisely the population the weight-management approval rests on. STEP 1 and SELECT both enrolled adults without diabetes. People with diabetes tend to lose somewhat less weight on the same dose, a pattern seen consistently across this drug class.
Compounded semaglutide is not an FDA-approved product, and it has not been reviewed for safety, effectiveness or quality. Wide-scale compounding was permitted while semaglutide sat on the FDA shortage list; once the shortage was resolved and the drug came off that list, the legal basis for routine compounding largely disappeared. The FDA has issued warning letters to sellers marketing compounded versions as equivalent to the approved products. Questions worth asking include what form of the ingredient is used and where it was produced.
The two were compared directly in SURMOUNT-5, where tirzepatide produced 20.2% average weight loss at 72 weeks against 13.7% for semaglutide 2.4 mg. Tirzepatide activates two receptors, GLP-1 and GIP, while semaglutide activates GLP-1 alone. Weight loss is not the only consideration: semaglutide has the larger cardiovascular outcomes dataset, holds the MASH indication, and carries no special oral contraceptive instruction.
Unused pens are kept refrigerated and protected from light until their expiration date, never frozen. The label permits a limited period at room temperature, and the exact allowance differs by product and pen, so the Instructions for Use that came with your pen is the authority rather than general advice. Pens are single-patient devices and should never be shared, even with a new needle, because of the risk of transmitting bloodborne infection.
The injection can be taken with or without food, at any time of day. The tablets are different and more demanding: they are taken once daily on an empty stomach with a small sip of water, and food, other drinks and other oral medications are held off for a period afterward, because absorption of oral semaglutide is easily disrupted. Follow the specific timing on your prescription.
Usually not, but tell your surgical and anesthesia team well in advance. Multisociety guidance published in October 2024 concluded that most people can continue GLP-1 medications before elective surgery, with extra precautions for those at higher risk of food remaining in the stomach: people still increasing their dose, people on higher doses, and anyone with nausea, vomiting, bloating or constipation around the time of the procedure. Those precautions can include a liquid diet for 24 hours beforehand. Follow the specific instructions your procedure team gives you.
In people with obesity, it did in a trial. STEP 9, published in 2024, found that knee pain scores improved by 41.7 points on semaglutide 2.4 mg against 27.5 points on placebo over 68 weeks, alongside 13.7% weight loss against 3.2%. The trial did not examine whether joint structure changed, and knee osteoarthritis is not an approved indication, so the result supports weight reduction as a route to less pain rather than semaglutide as an arthritis treatment.
No. The evoke and evoke+ phase 3 trials tested oral semaglutide for two years in 3,808 people with mild cognitive impairment or mild dementia due to Alzheimer's disease and found no significant slowing of progression compared with placebo. Some disease markers moved favourably, but that did not translate into any measurable clinical benefit, and the planned trial extension was discontinued.
Early trials suggest it may reduce drinking, but it is not approved for that purpose. A small 2025 trial found less drinking and craving on low-dose semaglutide over nine weeks, and a 2026 trial of 108 people with alcohol use disorder and obesity found heavy drinking days fell further on semaglutide than on placebo when combined with therapy. Both trials were small, and established treatments for alcohol use disorder have much more evidence behind them.
GLP-1 is a hormone the small intestine releases after a meal. It is part of what physiologists call the incretin effect: the reason eating glucose triggers a far larger insulin response than the same glucose delivered straight into a vein. Natural GLP-1 is broken down within minutes by an enzyme called DPP-4, which makes it useless as a medication in its native form. Semaglutide is a re-engineered version that shares roughly 94% of its sequence with the human hormone, modified at the points where that enzyme would otherwise cut it, and fitted with a fatty acid chain that binds it loosely to albumin in the blood. Those changes stretch its half-life to about a week, which is what makes once-weekly injection possible.
Once it reaches the GLP-1 receptor, several things happen at once. The pancreas releases more insulin, but only when blood sugar is elevated, which is why the medication carries little hypoglycemia risk on its own. Glucagon, the hormone the liver uses to push blood sugar up, is suppressed. The stomach empties more slowly, so food stays put longer and fullness lasts. And because GLP-1 receptors also sit in brain regions that regulate appetite, hunger signalling itself quiets down. That last effect is the one most people notice first: food simply occupies less mental space. The same mechanism explains the most common side effects, since slowed gastric emptying is also what produces nausea, reflux and constipation.
Semaglutide reaches patients under several names, and the confusion between them is one of the most common sources of misunderstanding. Ozempic is the weekly injection approved for type 2 diabetes, reaching a maximum of 2 mg. Rybelsus is the daily tablet approved for type 2 diabetes, first cleared in 2019 as the first oral GLP-1 of any kind. Wegovy is the weight-management brand: a weekly injection that titrates to 2.4 mg, a higher-dose 7.2 mg version called Wegovy HD, and since December 2025 a 25 mg once-daily tablet.
The distinction matters for reasons beyond naming. A medication's approved indication determines what evidence regulators reviewed, what the label instructs, and frequently whether insurance will cover it. Wegovy now carries three separate indications, which is unusual: chronic weight management, reduction of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and noncirrhotic MASH with moderate to advanced fibrosis. The label also states that semaglutide products should not be combined with each other or with any other GLP-1 receptor agonist.
Every Wegovy injection prescription begins at 0.25 mg once weekly for four weeks, then rises through 0.5 mg, 1 mg and 1.7 mg before reaching the 2.4 mg maintenance dose at around week 16. None of those early doses is meant to be therapeutic. They exist solely to let the gastrointestinal tract adapt, because starting at a full dose produces nausea severe enough that many people would abandon treatment. The oral tablets follow their own escalation through 1.5, 4 and 9 mg strengths before the 25 mg maintenance dose.
Titration is not rigid. If side effects at a given step are difficult, a provider may hold that dose longer before advancing, or settle at a lower maintenance dose that is tolerable. The injection can be given in the abdomen, thigh or upper arm, at any time of day, with or without food, with the site rotated each week. The tablets are stricter: taken on an empty stomach with a small amount of water, holding off food, other drinks and other oral medications for a set period afterward, because oral absorption of a peptide is fragile and easily disrupted.
STEP 1, published in the New England Journal of Medicine in 2021, is the trial that established semaglutide for weight management. It enrolled 1,961 adults with a BMI of 30 or above, or 27 with at least one weight-related condition, none of whom had diabetes, and randomized them two to one to semaglutide 2.4 mg weekly or placebo for 68 weeks, both alongside lifestyle counselling. Average weight change was a 14.9% reduction on semaglutide against 2.4% on placebo, roughly 15.3 kg versus 2.6 kg. The proportions matter as much as the average: 86.4% lost at least 5% of their body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%, compared with 31.5%, 12% and 4.9% on placebo.
Later trials in the programme filled in the picture. STEP TEENS tested adolescents aged 12 to 17 and found a 16.1% reduction in BMI at 68 weeks versus a slight increase on placebo, which supported the 2022 pediatric expansion. STEP UP tested the higher 7.2 mg dose and reported 18.7% average weight loss at 72 weeks, with 31.2% of participants losing a quarter or more of their body weight, at the cost of more gastrointestinal effects and markedly more dysesthesia. Across the programme the pattern is consistent: substantial average loss, wide individual variation, and results that depend on staying at an effective dose.
SELECT tested something weight trials cannot: whether the drug prevents cardiovascular events. It enrolled 17,604 adults aged 45 and older with established cardiovascular disease and a BMI of 27 or higher, none with diabetes, and followed them for a mean of about 40 months. Semaglutide reduced major adverse cardiovascular events, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke, by 20% compared with placebo, with a hazard ratio of 0.80. All three components of that composite contributed. This finding is the basis for the cardiovascular indication on the Wegovy label.
Prespecified analyses of the same dataset extended the picture. Weight loss continued for roughly 65 weeks and was sustained across four years, averaging 10.2% at 208 weeks against 1.5% on placebo. A composite kidney outcome occurred less often on semaglutide, 1.8% versus 2.2%. Benefits held across heart failure subtypes, and roughly a third of the cardiovascular benefit appeared to be mediated by reduction in waist circumference specifically rather than weight alone, which suggests visceral fat is doing meaningful work in the mechanism.
Semaglutide was a diabetes drug before it was a weight management drug, and the diabetes evidence is older and in some respects deeper. Ozempic, the weekly injection, and Rybelsus, the daily tablet, were each tested in large programmes of trials measuring blood sugar control, and each was also tested for cardiovascular safety, because regulators require that of any new diabetes medication.
The injectable's cardiovascular trial, SUSTAIN-6, was published in the New England Journal of Medicine in 2016. It randomized 3,297 people with type 2 diabetes and high cardiovascular risk to semaglutide 0.5 mg or 1 mg weekly, or placebo, and followed them for a median of about two years. The combined rate of cardiovascular death, non-fatal heart attack and non-fatal stroke was 6.6% on semaglutide against 8.9% on placebo, a 26% relative reduction. The trial was designed to show safety rather than benefit, and it was not large enough to settle the individual components: non-fatal stroke fell significantly, heart attacks fell but not significantly, and cardiovascular death was essentially unchanged.
The oral form has its own cardiovascular trial. SOUL, published in 2025, enrolled 9,650 people aged 50 or older with type 2 diabetes and established cardiovascular disease, chronic kidney disease or both, and followed them for a median of just over four years on oral semaglutide 14 mg daily or placebo. Major adverse cardiovascular events occurred in 12.0% on semaglutide against 13.8% on placebo, a 14% relative reduction, without an increase in serious adverse events. Rybelsus now carries a cardiovascular risk reduction indication for adults with type 2 diabetes at elevated risk, consistent with that result.
Two points help in reading these trials alongside the weight management evidence. First, the doses differ: diabetes dosing tops out at 2 mg weekly for the injection, below the 2.4 mg used for weight management. Second, the populations differ: SUSTAIN-6 and SOUL enrolled people with diabetes, while SELECT enrolled people without it. Each trial describes its own population at its own dose, and they support each other rather than substituting for one another.
One finding from SUSTAIN-6 has shaped how semaglutide is prescribed to people with diabetes ever since. Complications of diabetic retinopathy, the damage diabetes causes to the blood vessels at the back of the eye, occurred in 3.0% of participants on semaglutide against 1.8% on placebo. The complications counted included the need for laser treatment or injections into the eye, bleeding inside the eye, and blindness related to diabetes.
The leading explanation is not a direct toxic effect of the drug but a phenomenon known long before GLP-1 medications existed. When blood sugar falls quickly in someone whose eyes are already damaged, existing retinopathy can temporarily worsen. The same early worsening was observed decades ago when intensive insulin treatment was introduced. In SUSTAIN-6, the excess complications were concentrated among participants who already had retinopathy at the start and whose blood sugar dropped sharply early in treatment, which fits that explanation.
The practical consequence appears in the label rather than as a prohibition. People with diabetes and a history of diabetic retinopathy should be monitored for progression, and the label notes that rapid improvement in glucose control has been associated with temporary worsening. In practice that means a recent eye examination before starting and follow-up examinations during treatment for anyone with known retinopathy, rather than avoiding the medication. A dedicated long-term trial examining semaglutide's effect on diabetic eye disease was designed specifically to answer the question more precisely.
This signal is separate from the question of non-arteritic anterior ischemic optic neuropathy discussed elsewhere on this page. Retinopathy affects the retina and is linked to changes in blood sugar in people with diabetes. NAION affects the optic nerve and has been raised in people with and without diabetes. The two are sometimes merged in online discussion, but they are different conditions with different proposed mechanisms, and any new visual symptom, whichever the cause, warrants prompt assessment.
For someone with diabetes who already has retinopathy, the practical steps are straightforward. It helps to know the date and result of the most recent dilated eye examination before starting, and to share it with the prescriber. It is reasonable to ask whether the dose will be increased more gradually, since the concern relates to how quickly blood sugar falls rather than to the medication itself. Scheduling follow-up eye examinations during the first year of treatment, when blood sugar changes most, is sensible. Reporting any change in vision promptly, rather than waiting for the next routine appointment, completes the picture. These steps allow the metabolic and cardiovascular benefits of treatment to be pursued while keeping watch on the eyes.
Peptides are notoriously difficult to deliver by mouth. Stomach acid degrades them and the intestinal wall does not readily absorb molecules of that size, which is why almost every GLP-1 medication has been an injection. Oral semaglutide solves this with an absorption enhancer called SNAC, formulated into the tablet itself, which locally raises pH and helps the peptide cross the stomach lining before it can be broken down. The mechanism is fragile enough that dosing instructions are strict: an empty stomach, a small sip of water, and a waiting period before anything else is consumed.
The OASIS 4 trial tested the 25 mg daily tablet against placebo in 307 adults with obesity or overweight plus a weight-related condition, over 64 weeks. Average weight loss was 13.6% versus 2.2% on placebo under the treatment-policy analysis, and 16.6% among participants who adhered fully to treatment, with about a third of adherent participants losing at least 20% of their body weight. Side effects mirrored the injection, dominated by gastrointestinal symptoms. The FDA approved the tablet in December 2025 as the first oral GLP-1 for weight management, and it reached the US market in early January 2026.
Metabolic dysfunction-associated steatohepatitis, abbreviated MASH and formerly called NASH, is a progressive liver disease in which fat accumulation drives inflammation and scarring. Left untreated it can advance to cirrhosis, liver cancer or liver failure. An estimated 14.9 million American adults are affected, and prevalence tracks the rise in obesity and type 2 diabetes. Until recently there were almost no approved pharmacologic options.
The phase 3 ESSENCE trial enrolled 800 adults with MASH and stage F2 to F3 fibrosis. At 72 weeks, about 63% of those on semaglutide 2.4 mg achieved resolution of steatohepatitis without worsening fibrosis, against 34% on placebo, and 37% showed fibrosis improvement without worsening steatohepatitis, against 22%. A third achieved both endpoints, versus 16% on placebo. On that basis the FDA granted accelerated approval in August 2025 for noncirrhotic MASH with moderate to advanced fibrosis, making semaglutide the first GLP-1 with a liver indication. Accelerated approval means confirmation is still pending: part two of ESSENCE, which tests whether the drug reduces liver-related clinical events over 240 weeks, is expected to report in 2029. It is not approved for MASH with cirrhosis.
Semaglutide carries a boxed warning, the FDA's most serious label warning, for thyroid C-cell tumors. It rests on rodent studies in which the drug caused these tumors at exposures comparable to human doses. Whether that finding translates to people is unknown, because rodent and human thyroid C-cells differ in relevant ways. Regardless, it is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2, and providers are expected to counsel patients on symptoms worth reporting: a neck lump, hoarseness, difficulty swallowing or persistent shortness of breath.
Beyond the boxed warning, the label flags acute pancreatitis, gallbladder disease including gallstones, acute kidney injury usually stemming from dehydration through vomiting or diarrhea, worsening of existing diabetic retinopathy when blood sugar improves rapidly, serious hypersensitivity reactions including anaphylaxis, and increased hypoglycemia risk when combined with insulin or sulfonylureas. Day to day, the dominant complaints are gastrointestinal: nausea, vomiting, diarrhea and constipation, affecting roughly three-quarters of participants in the oral trial versus about 42% on placebo, mostly mild to moderate and concentrated around dose increases.
Two safety questions remain unsettled. A possible link to non-arteritic anterior ischemic optic neuropathy, a rare cause of sudden vision loss in one eye, emerged from a 2024 Harvard study and later database analyses; European regulators reviewed the evidence and concluded it is a very rare side effect warranting a label mention, while US labels did not carry that warning as of this writing. Separately, reports of severe, persistent gastroparesis have prompted ongoing regulatory attention across the GLP-1 class. Neither question is resolved, and both are reasonable to raise with a prescriber.
An extension of STEP 1 followed participants for a year after treatment ended. Those who had lost an average of 17.3% of their body weight regained about 11.6 percentage points of it by week 120, finishing roughly 5.6% below their starting weight. Improvements in blood pressure, cholesterol and blood sugar drifted back toward baseline over the same period. The finding is consistent with how obesity medicine now frames these drugs: the physiology that drives weight regain does not disappear while the medication is working, it is suppressed, and it resumes when the drug is withdrawn. That reasoning is why treatment is generally discussed as long-term rather than as a finite course, and why stopping is a decision worth planning with a provider rather than making abruptly.
During the semaglutide shortage, federal rules allowed compounding pharmacies to produce their own versions, and a large market grew around them. Compounded drugs are not FDA-approved: they are not reviewed for safety, effectiveness or manufacturing quality, and their potency and purity are not verified the way an approved product's are. Once the shortage was resolved and semaglutide came off the FDA shortage list, the legal basis for routine compounding largely fell away, and a federal court upheld that position. The FDA has issued warning letters to sellers advertising compounded semaglutide as equivalent to Ozempic or Wegovy, which it is not. Anyone currently using a compounded version has reason to ask what form of the ingredient it contains and which facility produced it.
The GLP-1 story starts with a puzzle. Researchers noticed decades ago that swallowing glucose triggers a far larger insulin response than receiving the same amount of glucose intravenously. Something released by the gut, not the glucose itself, was amplifying the signal. That something turned out to include glucagon-like peptide-1, released by the small intestine after a meal. It was an obvious drug candidate and an impossible one: natural GLP-1 is destroyed within minutes by an enzyme called DPP-4, far too quickly to be useful as a medicine.
The first workaround came from an unlikely source. A peptide found in the venom of the Gila monster, a lizard native to the American southwest, turned out to closely resemble human GLP-1 while resisting the enzyme that degrades it. That peptide became exenatide, the first GLP-1 receptor agonist approved for type 2 diabetes, given twice daily. It proved the concept but required frequent injection, and the search continued for something longer-lasting.
Semaglutide represents the engineered answer. It shares about 94% of its sequence with human GLP-1, with two deliberate changes. One substitutes a single amino acid at the point where DPP-4 would cut, blocking degradation. The other attaches a fatty acid chain that binds loosely and reversibly to albumin, the most abundant protein in blood. Bound to albumin, the drug is shielded from clearance and released gradually, which stretches its half-life to about a week. That is the entire basis for once-weekly dosing.
The same design principle explains why the drug's effects build slowly and fade slowly. It takes roughly four to five weeks at a given dose for blood levels to stabilize, which is why titration steps are spaced four weeks apart, and why a missed dose does not cause an immediate loss of effect. It is also why the drug has to be stopped well in advance of a planned pregnancy: a medication that takes weeks to accumulate takes weeks to clear.
STEP 1 is the trial everyone quotes, but it was one of several, and the others answer questions STEP 1 could not. Each was designed around a different population or a different question, and together they describe the drug more completely than any single result does. Reading them as a set also guards against the common error of treating one trial's average as a universal prediction.
The clearest pattern across the programme is that people with type 2 diabetes lose less weight on the same dose than people without it. This is consistent across the GLP-1 class and is not fully explained, though it likely reflects differences in the underlying metabolic state. It matters practically: someone with diabetes reading the 14.9% figure from STEP 1 should expect a smaller result, and a clinic quoting that figure to a patient with diabetes is quoting the wrong trial.
The adolescent trial, STEP TEENS, tested participants aged 12 to 17 and reported a 16.1% reduction in BMI at 68 weeks against a slight increase on placebo, which supported the 2022 expansion of the label to that age group. The higher-dose STEP UP trial tested 7.2 mg weekly and produced 18.7% average weight loss at 72 weeks versus 3.9% on placebo, with roughly a third of participants losing a quarter or more of their body weight, at the cost of more gastrointestinal effects and considerably more dysesthesia.
The withdrawal extension of STEP 1 is arguably the most important result in the whole programme, and the least quoted. Participants who had lost an average of 17.3% of their body weight regained about 11.6 percentage points of it within a year of stopping, ending roughly 5.6% below baseline, with cardiometabolic improvements drifting back toward where they started. Any discussion of semaglutide that omits this is describing half the picture.
The headline from SELECT is a 20% reduction in major adverse cardiovascular events across 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. What makes the trial significant is not just the size of that number but the type of evidence it represents. Most weight management claims rest on changes in weight, or on biomarkers such as cholesterol and inflammatory markers. SELECT counted actual events: cardiovascular deaths, heart attacks and strokes, over a mean follow-up of about 40 months.
A prespecified analysis presented later examined total events rather than just the first one per participant, which matters because people who have one cardiovascular event often have more. Semaglutide reduced both first events and total events across an expanded composite that added coronary revascularization and hospitalization for unstable angina. Coronary revascularization accounted for a substantial share of events, particularly subsequent ones, which tells you something about what the trial population was actually experiencing.
Other prespecified analyses extended the picture in useful directions. Weight loss continued for roughly 65 weeks before leveling off and was sustained across four years, averaging 10.2% at 208 weeks against 1.5% on placebo, with waist circumference down 7.7 cm. A kidney composite outcome occurred less often on semaglutide. Benefits held in participants with heart failure, across both preserved and reduced ejection fraction. Notably, roughly a third of the cardiovascular benefit appeared to be mediated specifically through reduction in waist circumference rather than weight generally, which points to visceral fat as part of the mechanism.
One limitation deserves emphasis. SELECT enrolled people who already had cardiovascular disease, so it demonstrates benefit in secondary prevention: reducing further events in people who have already had one. It does not establish that semaglutide prevents a first cardiovascular event in someone without established disease, and the label's cardiovascular indication reflects that boundary. Extending the finding beyond the population studied is exactly the kind of overreach worth watching for.
The FLOW trial was the first dedicated kidney outcomes study of semaglutide. It is important to be precise about who it enrolled, because the population differs from every other trial described on this page. FLOW studied 3,533 people who had both type 2 diabetes and chronic kidney disease, and it used the 1 mg weekly dose of semaglutide, the diabetes dose, not the 2.4 mg weight management dose. Median follow-up was about 3.4 years.
The primary outcome was a composite of kidney failure, a persistent 50% or greater fall in estimated kidney filtration rate, kidney death or cardiovascular death. Semaglutide reduced the risk of that composite by 24% compared with placebo. In the same trial, the combination of cardiovascular death, non-fatal heart attack and non-fatal stroke fell by 18%, consistently across degrees of kidney disease severity, including advanced disease.
Two caveats belong alongside those numbers, and independent reviewers have made both. First, the composite mixed outcomes that matter directly to patients, such as kidney death, with surrogate measures, such as a 50% drop in filtration rate, and the result was driven substantially by the surrogate component and by cardiovascular death rather than by dialysis or kidney-related death individually. Second, FLOW was stopped early for benefit. Trials halted early on prespecified criteria tend to overestimate the size of an effect, sometimes considerably, which is a recognized statistical phenomenon rather than a criticism of the investigators.
A separate prespecified analysis looked at whether taking an SGLT2 inhibitor, another class with kidney benefits, changed the picture. The overall benefit of semaglutide held regardless, though the analysis was not powered to detect smaller differences between those subgroups. Note what this section does not claim: FLOW does not establish kidney benefit in people without diabetes, and it does not establish that the 2.4 mg weight management dose produces the same effect. Those are different questions that this trial did not ask.
Heart failure with preserved ejection fraction is a form of heart failure in which the heart pumps a normal proportion of its blood with each beat but is stiff and fills poorly. It is closely tied to obesity, it causes breathlessness, fatigue and swelling, and for years it had few effective treatments. The STEP-HFpEF trial asked whether semaglutide could improve it.
The trial, published in the New England Journal of Medicine in 2023, randomized 529 adults with this form of heart failure and a BMI of 30 or more, none with diabetes, to semaglutide 2.4 mg weekly or placebo for 52 weeks. Its main measure was the Kansas City Cardiomyopathy Questionnaire, a validated score of heart failure symptoms and physical limitations. Scores improved by 16.6 points on semaglutide against 8.7 on placebo. Body weight fell by 13.3% against 2.6%. Distance walked in six minutes rose by about 21 metres against about 1 metre, and C-reactive protein, a marker of inflammation, fell by 43.5% against 7.3%.
Serious adverse events were less common on semaglutide than on placebo, at 13.3% against 26.7%, driven largely by fewer cardiac events. That is an encouraging safety signal in a population where worsening heart failure is common, but the trial was not designed or sized to measure heart failure hospitalizations or deaths as its primary question.
The limitations are worth stating alongside the results. Participants were overwhelmingly white, follow-up lasted one year, very few were taking SGLT2 inhibitors, now a standard treatment for this condition, and people with diabetes were excluded, although a companion trial studied that group. The trial establishes that semaglutide improves symptoms, function and weight in obesity-related heart failure with preserved ejection fraction. It does not by itself establish effects on hospitalization or survival, which are the outcomes that matter most over time.
Excess weight loads the knee joint with every step, and knee osteoarthritis is one of the most common and disabling conditions associated with obesity. The STEP 9 trial, published in the New England Journal of Medicine in 2024, asked whether semaglutide could reduce the pain it causes.
The trial randomized adults with a BMI of 30 or more and moderate knee osteoarthritis to semaglutide 2.4 mg weekly or placebo in a two to one ratio for 68 weeks, alongside lifestyle counselling. Its main measure of pain was the WOMAC pain score, a standard osteoarthritis questionnaire. Pain improved by 41.7 points on semaglutide against 27.5 points on placebo. Body weight fell by 13.7% against 3.2%. Physical function, measured with a standard quality-of-life questionnaire, also improved more on semaglutide.
The size of the placebo improvement is worth noticing. Pain scores fell substantially in the placebo group too, which is common in osteoarthritis trials and reflects lifestyle counselling, natural fluctuation in symptoms and the expectation effects that accompany any trial. The meaningful figure is the difference between the groups, which was clear and statistically robust.
The trial also has limits that matter for interpretation. It did not include imaging to assess whether the structure of the joint changed, so it shows that pain and function improved but not whether the disease itself was slowed. Most participants were women, which may limit how well the result applies to men. Discontinuation because of adverse events was more common on semaglutide, at 6.7% against 3.0%. The finding supports weight reduction as a way to relieve osteoarthritis pain; it does not make semaglutide a treatment for osteoarthritis in people without obesity, and it is not an approved indication.
Gastrointestinal effects are the reason most people who stop semaglutide stop it, and they follow a predictable pattern. Nausea, vomiting, diarrhea, constipation and abdominal discomfort cluster in the first weeks of treatment and around each dose increase, then generally settle at a given dose. In the oral semaglutide trial, gastrointestinal events affected 74% of participants versus 42% on placebo, and were mostly mild or moderate. Knowing the pattern in advance makes the early weeks easier to interpret.
The practical measures most often suggested follow directly from the mechanism. Because the stomach empties more slowly, large meals sit longer and produce more discomfort, so smaller portions eaten more often tend to be tolerated better. Fatty, fried and heavily spiced foods empty slowest and are the usual culprits behind the worst episodes. Eating slowly and stopping before feeling completely full matters more than it did before treatment, because the signal that arrives when you are full now arrives later and more forcefully.
Constipation is common and often under-addressed, and dehydration compounds it, particularly when appetite loss reduces fluid intake alongside food. Adequate fluids and fiber are the usual first response. Dehydration also matters for a more serious reason: acute kidney injury in this context usually arises from fluid loss through vomiting or diarrhea rather than from any direct effect of the drug on the kidney, which is why persistent vomiting is worth reporting rather than enduring.
When symptoms are severe, the usual response is to hold the current dose longer rather than continue escalating, or to settle at a lower maintenance dose that is tolerable. A lower dose taken consistently generally achieves more than a higher dose abandoned. There is a line, though, between expected adjustment and warning signs: severe persistent abdominal pain, particularly radiating to the back, warrants prompt medical attention rather than dietary adjustment, because acute pancreatitis is a listed rare adverse event and the label directs that the drug be stopped if it is suspected.
People taking semaglutide often describe a reduction in what has come to be called food noise: the persistent background thinking about food, cravings and the next meal. The phrase is informal, but there is controlled evidence behind the experience it describes.
A double-blind trial published in Diabetes, Obesity and Metabolism in 2021 randomized 72 adults with obesity to semaglutide 2.4 mg weekly or placebo for 20 weeks and then measured what they ate when offered an unrestricted lunch. Participants on semaglutide ate 35% less energy than those on placebo. They also reported less hunger, more fullness and satiety, better control of eating, and fewer and weaker food cravings on a standard eating-behaviour questionnaire. Over the same 20 weeks, body weight fell by 9.9% on semaglutide against 0.4% on placebo.
The same trial produced a finding that refines the usual explanation for how the drug works. Semaglutide is often said to cause weight loss by slowing the emptying of the stomach, and it does slow gastric emptying at the start of treatment. By 20 weeks, however, the trial found no meaningful delay in gastric emptying at the one-hour mark and only a small effect over five hours that disappeared once body weight was taken into account. The appetite effect, by contrast, persisted. That pattern points to the drug's action on appetite centres in the brain as the main driver of sustained weight loss, with slowed gastric emptying contributing more to early side effects than to long-term results.
This has practical meaning. Early nausea often reflects the stomach-emptying effect and tends to settle, while reduced appetite tends to continue. It also explains why appetite typically returns after stopping: the drug is suppressing a signal, not permanently changing it, which fits the weight regain seen in the STEP 1 withdrawal extension.
A reduced appetite changes what matters about food. When someone is eating substantially less, each meal carries more of the job of supplying protein, vitamins, minerals and fibre, so the quality of a smaller diet matters more than it did before. Protein in particular deserves attention because it supports the preservation of lean tissue during weight loss, and fluids deserve attention because thirst cues can fade along with hunger. Skipping meals entirely because hunger is absent can leave nutritional gaps and contribute to fatigue, dizziness and constipation. None of this requires a special protocol, but it does mean that eating less works best when it is still eating well, and a dietitian can help translate that into a practical plan.
Because GLP-1 medications can slow stomach emptying, anesthesiologists became concerned that some patients taking them might have food in the stomach at the time of surgery despite fasting as instructed. Food in the stomach during anesthesia raises the risk of aspiration, in which stomach contents enter the lungs. Early guidance in 2023 suggested holding weekly GLP-1 injections for a week before elective procedures.
That advice was revised. In October 2024, the American Society of Anesthesiologists joined the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity and the Society of American Gastrointestinal and Endoscopic Surgeons in multisociety guidance. It concluded that most patients can continue their GLP-1 medication before elective surgery, with management tailored to individual risk rather than a blanket instruction to stop.
The guidance identified who is at highest risk: people in the dose escalation phase, people on higher doses, and anyone with active gastrointestinal symptoms such as nausea, vomiting, abdominal pain, bloating or constipation around the time of the procedure. For those patients it suggested measures including a liquid diet for 24 hours before the procedure, point-of-care ultrasound to check the stomach before anesthesia, and deferring elective procedures in people with active symptoms or who are mid-escalation. It also cautioned against stopping these medications simply because a patient has obesity.
The practical message is simple and does not depend on the details changing. Anyone taking semaglutide should tell the surgical and anesthesia team well before any procedure, including endoscopy and dental sedation, and follow the specific instructions that team gives. Stopping the medication independently is not necessary for most people and has its own consequences, including loss of blood sugar control in people with diabetes and the need to re-titrate from a lower dose afterwards.
Weight lost through a substantial calorie deficit is never purely fat. Some proportion comes from lean tissue, which includes muscle, and this is true of any effective weight loss method, including diet alone and bariatric surgery. It is not a peculiarity of GLP-1 medications, though the speed and magnitude of loss these drugs produce makes the question more pressing than it is with slower approaches.
The standard responses are adequate protein intake and regular resistance training, both of which have good general evidence for preserving lean mass during weight loss. What does not exist is trial evidence showing that any particular protein target or training protocol, combined with semaglutide specifically, produces better long-term outcomes. The advice is sound and grounded in wider exercise and nutrition research; it is simply not something the semaglutide trials tested, and any source presenting a specific protocol as proven alongside this drug is overstating what is known.
There is a distinction worth drawing between lean mass and function. Losing lean tissue while becoming stronger, fitter and more mobile is a different situation from losing lean tissue while becoming weaker, and the scale cannot tell them apart. Measures of function, such as what you can lift and how easily you move, are more informative than a body composition percentage on its own. In SELECT, lean body mass was not the focus, but physical functioning scores improved rather than declined across the trial population.
Bone density is a related and less discussed question. Weight loss by any means is associated with some reduction in bone mineral density, and the long-term fracture implications of sustained GLP-1 treatment have not been established in dedicated trials. This is genuinely unknown rather than reassuring or alarming, and it is a reasonable thing to raise with a provider, particularly for anyone with existing bone density concerns or other fracture risk factors.
Three different things get grouped together under the heading of non-brand semaglutide, and they are not equivalent. The first is compounded semaglutide made by a licensed pharmacy. The second is material sold online under a research use only label. The third is outright counterfeit product presented as genuine Ozempic or Wegovy. Each carries different risks and different legal standing, and treating them as one category makes it harder to think clearly about any of them.
Compounding became widespread for a specific regulatory reason. When a drug is on the FDA shortage list, pharmacies are permitted latitude to compound versions of it that would otherwise be prohibited. Semaglutide was on that list, and a large market grew accordingly. Once the shortage was resolved and semaglutide came off the list, that latitude largely disappeared, and a federal court upheld the position that compounding pharmacies could no longer produce their own versions. Compounded drugs are not FDA-approved: they are not reviewed for safety, effectiveness or manufacturing quality, and their potency and purity are not verified as an approved product's are.
The FDA has issued warning letters to sellers marketing compounded semaglutide as equivalent to the approved products, on the grounds that such claims are false or misleading because the products are not the same thing. A separate issue concerns the chemical form: some compounded preparations used semaglutide salt forms rather than the base form present in the approved products, and these are not established as equivalent. Asking which form a preparation contains, and which facility produced it, is a reasonable question that a legitimate pharmacy will answer.
Material sold under a research use only label is a separate category again. That label does not authorize human use, regardless of how the product is marketed, and nobody has verified its identity, purity, sterility or concentration. Injecting an unverified sterile preparation adds infection and contamination risk to dosing uncertainty. Counterfeits are different still: products deliberately packaged to appear genuine, where the contents are unknown entirely. The practical protection against that last category is obtaining medication through a licensed pharmacy with a valid prescription.
For several years, semaglutide was one of the most closely watched candidates in Alzheimer's disease research. Observational studies of people with diabetes had suggested that those taking GLP-1 medications developed dementia less often, and laboratory research had shown effects on inflammation and brain metabolism. The evoke and evoke+ trials were designed to test that possibility properly.
The two phase 3 trials together enrolled 3,808 adults aged 55 to 85 with mild cognitive impairment or mild dementia due to Alzheimer's disease, with the disease confirmed by amyloid testing. Participants took oral semaglutide once daily or placebo for two years. The main measure was the Clinical Dementia Rating Sum of Boxes, a standard scale covering memory, orientation, judgment, community affairs, home life and personal care.
Neither trial showed a statistically significant slowing of disease progression compared with placebo, and secondary measures of cognition and daily functioning showed no clinically meaningful benefit. Some biological markers associated with the disease moved in a favourable direction, by up to about 10%, but those changes did not translate into any measurable clinical benefit within the trial period. Side effects matched semaglutide's known profile. The results were announced in late 2025, and the planned one-year extension was discontinued.
The evoke trials illustrate a pattern worth understanding. Observational associations can arise for reasons unrelated to the drug itself, such as differences in health, access to care or other treatments between people who are and are not prescribed a medication. Biomarker changes can move without clinical benefit following. A large randomized trial is the test that separates a genuine effect from those influences, and in this case the answer was negative. Semaglutide is not a treatment for Alzheimer's disease, and claims suggesting it protects the brain should be read in light of these results.
Reports that people taking GLP-1 medications lose interest in alcohol have prompted formal research. The biology is plausible: GLP-1 receptors are present in brain regions involved in reward, and animal studies have shown reduced alcohol consumption with GLP-1 drugs. Human trials are now testing whether that translates into treatment.
The first randomized trial of semaglutide in alcohol use disorder was published in JAMA Psychiatry in 2025. It gave 48 adults with alcohol use disorder low doses of semaglutide or placebo for nine weeks. Participants on semaglutide drank less in a laboratory session in which they could choose how much to drink, and in daily life they had fewer drinks on drinking days, larger reductions in heavy drinking days and less craving. Among participants who smoked, cigarette use also fell more on semaglutide. The investigators described the findings as preliminary.
A larger trial followed. The SEMALCO trial, published in The Lancet in 2026, randomized 108 adults in Denmark who were seeking treatment for alcohol use disorder and also had obesity to weekly semaglutide or placebo for six months, with everyone also receiving cognitive behavioural therapy. Heavy drinking days in the previous month fell from about 17 to about 5 on semaglutide, against about 9 on placebo. Total alcohol consumption fell further on semaglutide as well. The authors noted the trial's small size and the lack of follow-up after treatment ended.
These results are encouraging and early. Semaglutide is not approved to treat alcohol use disorder, the trials so far are small, and the larger trial studied people who also had obesity, so it does not show what happens in people without it. Established treatments for alcohol use disorder exist and have substantially more evidence. Anyone concerned about their drinking has good options to discuss with a clinician now, whatever the future of this research turns out to be.
The first question to ask of any semaglutide claim is which trial it comes from, because the trials studied different populations at different doses. STEP 1 studied adults without diabetes at 2.4 mg weekly and reported 14.9% average weight loss. FLOW studied people with diabetes and chronic kidney disease at 1 mg weekly and reported kidney outcomes. SELECT studied people with established cardiovascular disease at 2.4 mg and counted cardiovascular events. A figure lifted from one and applied to another describes something that was never measured.
The second is to distinguish an outcome from a biomarker. SELECT counted heart attacks, strokes and cardiovascular deaths, which are outcomes. Improvements in cholesterol, blood pressure or inflammatory markers are biomarkers: plausible indicators, but not proof that events were prevented. Semaglutide happens to have both kinds of evidence, which is unusual and worth recognizing. Most treatments marketed for metabolic health have only the second kind, and presenting biomarker changes in language that implies outcome evidence is the most common overstatement in this field.
The third is to separate an average from a prediction. A 14.9% average across 1,961 people describes the middle of a wide distribution: in STEP 1, about 14% of participants did not reach even 5% weight loss, while roughly half exceeded 15%. An average is a summary of what happened to a group, not a forecast for an individual, and a page that presents it as the latter is making a claim the trial does not support.
The fourth is to check whether a comparison is measuring the same thing on both sides. Semaglutide's headline percentages describe total body weight. Tesamorelin's describe visceral fat volume on CT. Those are different quantities, and setting them side by side implies an equivalence that does not exist. The same applies to comparisons between semaglutide and tirzepatide: SURMOUNT-5 compared them directly and found 20.2% versus 13.7% at 72 weeks, which is a fair comparison precisely because both figures came from the same trial measuring the same endpoint.
The most consequential unknown is what happens over decades. The longest exposure data comes from SELECT at four years, and obesity is a lifelong condition for which these drugs are framed as long-term therapy. Four years is substantial evidence and it is not the same as twenty. Anyone starting treatment in their thirties is, in a real sense, ahead of the evidence, and that is worth understanding rather than glossing over.
Two safety signals remain unresolved. A possible association with non-arteritic anterior ischemic optic neuropathy, a rare cause of sudden vision loss in one eye, emerged from a 2024 Harvard study and subsequent database analyses. European regulators reviewed the evidence and concluded it is a very rare side effect warranting a label mention; United States labels did not carry that warning as of this writing. Separately, reports of severe and persistent gastroparesis have prompted regulatory attention across the GLP-1 class. Neither question is settled in either direction.
The thyroid C-cell tumor question sits in a similar place. The boxed warning rests on rodent studies, and whether the finding translates to humans is unknown, because rodent and human thyroid C-cells differ in relevant ways. No human link has been established, and no study has been long enough or large enough to exclude a small effect entirely. A long-term epidemiological study is ongoing. Both of those statements are true at once, and quoting only one of them misrepresents the situation.
Several practical questions also lack answers. Adolescent data extends to 68 weeks, not to adulthood, so the effects of starting treatment at 12 and continuing for decades are unstudied. No trial has established the optimal approach to stopping, or whether any tapering strategy reduces weight regain. And the high discontinuation rate observed in practice, with research finding that a majority of people using GLP-1 drugs for weight loss stop within a year, mostly over cost and side effects, means real-world results often differ substantially from trial results achieved under close supervision.
This guide draws on FDA prescribing information, peer-reviewed clinical trial publications, regulatory announcements and professional society guidance. It is provided for general education and does not constitute medical advice. Speak with a licensed healthcare provider about any medication or treatment decision.